1. Home
  2. CYPH vs SWZ Comparison

CYPH vs SWZ Comparison

Compare CYPH & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cypherpunk Technologies Inc.

CYPH

Cypherpunk Technologies Inc.

HOLD

Current Price

$3.61

Market Cap

73.3M

Sector

Health Care

ML Signal

HOLD

Logo Swiss Helvetia Fund Inc. (The)

SWZ

Swiss Helvetia Fund Inc. (The)

HOLD

Current Price

$5.80

Market Cap

75.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYPH
SWZ
Founded
2011
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
73.3M
75.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CYPH
SWZ
Price
$3.61
$5.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 16.1M
25.6K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
★ 6.59%
EPS Growth
★ 103.87
N/A
EPS
N/A
★ N/A
Revenue
★ $1,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$5.76
52 Week High
$4.19
$6.31

Technical Indicators

Market Signals
Indicator
CYPH
SWZ
Relative Strength Index (RSI) 58.39 23.57
Support Level $0.69 N/A
Resistance Level $3.23 $6.00
Average True Range (ATR) 0.50 0.05
MACD 0.01 -0.02
Stochastic Oscillator 53.86 5.13

Price Performance

Historical Comparison
CYPH
SWZ

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

About SWZ Swiss Helvetia Fund Inc. (The)

Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.

Share on Social Networks: